European Biotech Acquisition Corp.

European Biotech Acquisition Corp. (Nasdaq: EBAC) is a blank-check company that completed its initial public offering in 2021, targeting acquisition opportunities in the European biotechnology and life sciences sector. The company filed an S-1/A amendment with the SEC on March 8, 2021, accession number 0000950103-21-003641, as part of its IPO registration process. EBAC was structured to pursue a merger or business combination with a European-focused biotech or pharmaceutical target. Investors and analysts tracking the SPAC lifecycle, deal pipeline, and filing history for EBAC can access comprehensive data, status updates, and document archives by signing up for full coverage on SpacDesk.